80 related articles for article (PubMed ID: 32666407)
1. Clinico-pathological and molecular characterization of diffuse midline gliomas: is there a prognostic significance?
Manjunath N; Jha P; Singh J; Raheja A; Kaur K; Suri A; Garg A; Sharma MC; Sarkar C; Mohan M; Mani K; Suri V
Neurol Sci; 2021 Mar; 42(3):925-934. PubMed ID: 32666407
[TBL] [Abstract][Full Text] [Related]
2. Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.
Gong X; Kuang S; Deng D; Wu J; Zhang L; Liu C
CNS Neurosci Ther; 2023 Dec; 29(12):3863-3875. PubMed ID: 37311690
[TBL] [Abstract][Full Text] [Related]
3. Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas.
Mosaab A; El-Ayadi M; Khorshed EN; Amer N; Refaat A; El-Beltagy M; Hassan Z; Soror SH; Zaghloul MS; El-Naggar S
Sci Rep; 2020 May; 10(1):8368. PubMed ID: 32433577
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy in H3K27M diffuse midline glioma.
Patel J; Aittaleb R; Doherty R; Gera A; Lau B; Messinger D; Wadden J; Franson A; Saratsis A; Koschmann C
Neuro Oncol; 2024 May; 26(Supplement_2):S101-S109. PubMed ID: 38096156
[TBL] [Abstract][Full Text] [Related]
5. H3K27M mutant glioma: Disease definition and biological underpinnings.
Saratsis AM; Knowles T; Petrovic A; Nazarian J
Neuro Oncol; 2024 May; 26(Supplement_2):S92-S100. PubMed ID: 37818718
[TBL] [Abstract][Full Text] [Related]
6. H3K27-altered diffuse midline gliomas with MAPK pathway alterations: Prognostic and therapeutic implications.
Gestrich C; Grieco K; Lidov HG; Baird LC; Fehnel KP; Yeo KK; Meredith DM; Alexandrescu S
J Neuropathol Exp Neurol; 2023 Dec; 83(1):30-35. PubMed ID: 38037182
[TBL] [Abstract][Full Text] [Related]
7. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
[TBL] [Abstract][Full Text] [Related]
8. Identification of a differentiation stall in epithelial mesenchymal transition in histone H3-mutant diffuse midline glioma.
Sanders LM; Cheney A; Seninge L; van den Bout A; Chen M; Beale HC; Kephart ET; Pfeil J; Learned K; Lyle AG; Bjork I; Haussler D; Salama SR; Vaske OM
Gigascience; 2020 Dec; 9(12):. PubMed ID: 33319914
[TBL] [Abstract][Full Text] [Related]
9. Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.
Bredel M; Espinosa L; Kim H; Scholtens DM; McElroy JP; Rajbhandari R; Meng W; Kollmeyer TM; Malta TM; Quezada MA; Harsh GR; Lobo-Jarne T; Solé L; Merati A; Nagaraja S; Nair S; White JJ; Thudi NK; Fleming JL; Webb A; Natsume A; Ogawa S; Weber RG; Bertran J; Haque SJ; Hentschel B; Miller CR; Furnari FB; Chan TA; Grosu AL; Weller M; Barnholtz-Sloan JS; Monje M; Noushmehr H; Jenkins RB; Rogers CL; MacDonald DR; Pugh SL; Chakravarti A
Cell Rep Med; 2023 Jun; 4(6):101082. PubMed ID: 37343523
[TBL] [Abstract][Full Text] [Related]
10. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways.
Venneti S; Kawakibi AR; Ji S; Waszak SM; Sweha SR; Mota M; Pun M; Deogharkar A; Chung C; Tarapore RS; Ramage S; Chi A; Wen PY; Arrillaga-Romany I; Batchelor TT; Butowski NA; Sumrall A; Shonka N; Harrison RA; de Groot J; Mehta M; Hall MD; Daghistani D; Cloughesy TF; Ellingson BM; Beccaria K; Varlet P; Kim MM; Umemura Y; Garton H; Franson A; Schwartz J; Jain R; Kachman M; Baum H; Burant CF; Mottl SL; Cartaxo RT; John V; Messinger D; Qin T; Peterson E; Sajjakulnukit P; Ravi K; Waugh A; Walling D; Ding Y; Xia Z; Schwendeman A; Hawes D; Yang F; Judkins AR; Wahl D; Lyssiotis CA; de la Nava D; Alonso MM; Eze A; Spitzer J; Schmidt SV; Duchatel RJ; Dun MD; Cain JE; Jiang L; Stopka SA; Baquer G; Regan MS; Filbin MG; Agar NYR; Zhao L; Kumar-Sinha C; Mody R; Chinnaiyan A; Kurokawa R; Pratt D; Yadav VN; Grill J; Kline C; Mueller S; Resnick A; Nazarian J; Allen JE; Odia Y; Gardner SL; Koschmann C
Cancer Discov; 2023 Nov; 13(11):2370-2393. PubMed ID: 37584601
[TBL] [Abstract][Full Text] [Related]
11. Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq.
Filbin MG; Tirosh I; Hovestadt V; Shaw ML; Escalante LE; Mathewson ND; Neftel C; Frank N; Pelton K; Hebert CM; Haberler C; Yizhak K; Gojo J; Egervari K; Mount C; van Galen P; Bonal DM; Nguyen QD; Beck A; Sinai C; Czech T; Dorfer C; Goumnerova L; Lavarino C; Carcaboso AM; Mora J; Mylvaganam R; Luo CC; Peyrl A; Popović M; Azizi A; Batchelor TT; Frosch MP; Martinez-Lage M; Kieran MW; Bandopadhayay P; Beroukhim R; Fritsch G; Getz G; Rozenblatt-Rosen O; Wucherpfennig KW; Louis DN; Monje M; Slavc I; Ligon KL; Golub TR; Regev A; Bernstein BE; Suvà ML
Science; 2018 Apr; 360(6386):331-335. PubMed ID: 29674595
[TBL] [Abstract][Full Text] [Related]
12. Does H3K27M Mutation Impact Survival Outcome of High-Grade Spinal Cord Astrocytoma?
Zhang F; Cheng L; Ding Z; Wang S; Zhao X; Zhao Z; Liang C; Wu K; Zhang D; Wang Y; Fan T
Neurospine; 2023 Dec; 20(4):1480-1489. PubMed ID: 38171314
[TBL] [Abstract][Full Text] [Related]
13. High-Grade Astrocytoma with Piloid Features: A Dual Institutional Review of Imaging Findings of a Novel Entity.
Soni N; Agarwal A; Ajmera P; Mehta P; Gupta V; Vibhute M; Gubbiotti M; Mark IT; Messina SA; Mohan S; Bathla G
AJNR Am J Neuroradiol; 2024 Apr; 45(4):468-474. PubMed ID: 38485198
[TBL] [Abstract][Full Text] [Related]
14. Letter: Diffuse Isocitrate Dehydrogenase-Mutant Gliomas With Histone H3 Alterations are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis.
Rahman S; Ahmed Khan R; Chowdhury M; Hasan M; Haque MR; Rahman MM
Neurosurgery; 2024 Apr; 94(4):e59-e60. PubMed ID: 38206039
[No Abstract] [Full Text] [Related]
15. BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.
Panditharatna E; Marques JG; Wang T; Trissal MC; Liu I; Jiang L; Beck A; Groves A; Dharia NV; Li D; Hoffman SE; Kugener G; Shaw ML; Mire HM; Hack OA; Dempster JM; Lareau C; Dai L; Sigua LH; Quezada MA; Stanton AJ; Wyatt M; Kalani Z; Goodale A; Vazquez F; Piccioni F; Doench JG; Root DE; Anastas JN; Jones KL; Conway AS; Stopka S; Regan MS; Liang Y; Seo HS; Song K; Bashyal P; Jerome WP; Mathewson ND; Dhe-Paganon S; Suvà ML; Carcaboso AM; Lavarino C; Mora J; Nguyen QD; Ligon KL; Shi Y; Agnihotri S; Agar NYR; Stegmaier K; Stiles CD; Monje M; Golub TR; Qi J; Filbin MG
Cancer Discov; 2022 Dec; 12(12):2880-2905. PubMed ID: 36305736
[TBL] [Abstract][Full Text] [Related]
16. Genomic alterations underlying spinal metastases in pediatric H3K27M-mutant pineal parenchymal tumor of intermediate differentiation: case report.
Fomchenko EI; Erson-Omay EZ; Kundishora AJ; Hong CS; Daniel AA; Allocco A; Duy PQ; Darbinyan A; Marks AM; DiLuna ML; Kahle KT; Huttner A
J Neurosurg Pediatr; 2019 Oct; 25(2):121-130. PubMed ID: 31653819
[TBL] [Abstract][Full Text] [Related]
17. Imaging findings of diffuse midline glioma with H3K27M mutation in the dorsal medulla oblongata: A rare case report.
Shan M; Cui L; Zhang X; Hou M
Asian J Surg; 2023 Dec; 46(12):5516-5518. PubMed ID: 37541876
[No Abstract] [Full Text] [Related]
18. Advances in Treatment of Diffuse Midline Gliomas.
Cacciotti C; Wright KD
Curr Neurol Neurosci Rep; 2023 Dec; 23(12):849-856. PubMed ID: 37921944
[TBL] [Abstract][Full Text] [Related]
19. PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.
Brown EJ; Balaguer-Lluna L; Cribbs AP; Philpott M; Campo L; Browne M; Wong JF; Oppermann U; Carcaboso ÁM; Bullock AN; Farnie G
Sci Rep; 2024 Jan; 14(1):328. PubMed ID: 38172189
[TBL] [Abstract][Full Text] [Related]
20. A road map for the treatment of pediatric diffuse midline glioma.
Koschmann C; Al-Holou WN; Alonso MM; Anastas J; Bandopadhayay P; Barron T; Becher O; Cartaxo R; Castro MG; Chung C; Clausen M; Dang D; Doherty R; Duchatel R; Dun M; Filbin M; Franson A; Galban S; Garcia Moure M; Garton H; Gowda P; Marques JG; Hawkins C; Heath A; Hulleman E; Ji S; Jones C; Kilburn L; Kline C; Koldobskiy MA; Lim D; Lowenstein PR; Lu QR; Lum J; Mack S; Magge S; Marini B; Martin D; Marupudi N; Messinger D; Mody R; Morgan M; Mota M; Muraszko K; Mueller S; Natarajan SK; Nazarian J; Niculcea M; Nuechterlein N; Okada H; Opipari V; Pai MP; Pal S; Peterson E; Phoenix T; Prensner JR; Pun M; Raju GP; Reitman ZJ; Resnick A; Rogawski D; Saratsis A; Sbergio SG; Souweidane M; Stafford JM; Tzaridis T; Venkataraman S; Vittorio O; Wadden J; Wahl D; Wechsler-Reya RJ; Yadav VN; Zhang X; Zhang Q; Venneti S
Cancer Cell; 2024 Jan; 42(1):1-5. PubMed ID: 38039965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
